Smith & Nephew (LON:SN) had its price objective cut by Morgan Stanley from GBX 1,558 ($21.53) to GBX 1,457 ($20.13) in a research note issued to investors on Tuesday morning. They currently have an equal weight rating on the stock.
A number of other analysts have also recently issued reports on SN. Berenberg Bank reiterated a hold rating and set a GBX 1,340 ($18.51) target price on shares of Smith & Nephew in a report on Friday, November 3rd. Credit Suisse Group boosted their price target on Smith & Nephew from GBX 1,285 ($17.75) to GBX 1,290 ($17.82) and gave the stock a neutral rating in a research report on Friday, February 9th. JPMorgan Chase & Co. reissued an overweight rating and set a GBX 1,411 ($19.49) price target on shares of Smith & Nephew in a research report on Wednesday, February 7th. Jefferies Group reissued a buy rating and set a GBX 1,515 ($20.93) price target on shares of Smith & Nephew in a research report on Monday, November 6th. Finally, Deutsche Bank boosted their price target on Smith & Nephew from GBX 1,200 ($16.58) to GBX 1,315 ($18.17) and gave the stock a hold rating in a research report on Monday, October 23rd. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and two have issued a buy rating to the stock. The company presently has an average rating of Hold and a consensus price target of GBX 1,334.73 ($18.44).
Shares of Smith & Nephew (LON:SN) opened at GBX 1,273 ($17.59) on Tuesday. Smith & Nephew has a fifty-two week low of GBX 1,173 ($16.21) and a fifty-two week high of GBX 1,442 ($19.92). The stock has a market capitalization of $11,060.00 and a PE ratio of 2,020.63.
The firm also recently announced a dividend, which will be paid on Wednesday, May 9th. Shareholders of record on Thursday, April 5th will be given a $0.23 dividend. This represents a dividend yield of 1.34%. This is a positive change from Smith & Nephew’s previous dividend of $0.12. The ex-dividend date is Thursday, April 5th.
In other Smith & Nephew news, insider Angie Risley bought 1,601 shares of the business’s stock in a transaction on Friday, February 9th. The shares were bought at an average cost of GBX 1,249 ($17.26) per share, with a total value of £19,996.49 ($27,627.09).
TRADEMARK VIOLATION NOTICE: “Smith & Nephew (SN) PT Lowered to GBX 1,457 at Morgan Stanley” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this article on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright law. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/02/16/smith-nephew-sn-pt-lowered-to-gbx-1457-at-morgan-stanley.html.
About Smith & Nephew
Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. Its products and services include Sports Medicine Joint Repair, Arthroscopic Enabling Technologies (AET), Trauma & Extremities, Other Surgical Businesses, Knee Implants, Hip Implants, Advanced Wound Care, Advanced Wound Bioactives and Advanced Wound Devices.
Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.